Takeda Pharmaceutical Co Ltd (NYSE:TAK) Shares Sold by Morningstar Investment Services LLC

Morningstar Investment Services LLC lessened its position in shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) by 6.7% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 62,082 shares of the company’s stock after selling 4,493 shares during the period. Morningstar Investment Services LLC’s holdings in Takeda Pharmaceutical were worth $1,124,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Cornerstone Advisors Inc. raised its stake in shares of Takeda Pharmaceutical by 40.2% during the 2nd quarter. Cornerstone Advisors Inc. now owns 4,407 shares of the company’s stock worth $79,000 after buying an additional 1,264 shares during the last quarter. JustInvest LLC acquired a new position in shares of Takeda Pharmaceutical during the 2nd quarter worth $313,000. Cambridge Investment Research Advisors Inc. acquired a new position in shares of Takeda Pharmaceutical during the 2nd quarter worth $204,000. Baldwin Investment Management LLC raised its stake in shares of Takeda Pharmaceutical by 4.4% during the 2nd quarter. Baldwin Investment Management LLC now owns 40,567 shares of the company’s stock worth $727,000 after buying an additional 1,700 shares during the last quarter. Finally, Lindbrook Capital LLC raised its stake in shares of Takeda Pharmaceutical by 31.3% during the 2nd quarter. Lindbrook Capital LLC now owns 5,598 shares of the company’s stock worth $100,000 after buying an additional 1,333 shares during the last quarter. 3.67% of the stock is owned by institutional investors and hedge funds.

TAK has been the subject of several research reports. Zacks Investment Research downgraded Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, June 30th. ValuEngine raised shares of Takeda Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Thursday, May 14th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $23.50.

TAK stock traded up $0.04 during trading on Friday, hitting $18.20. The stock had a trading volume of 916,874 shares, compared to its average volume of 1,000,042. The company’s 50 day moving average price is $17.93 and its two-hundred day moving average price is $17.90. Takeda Pharmaceutical Co Ltd has a 1-year low of $12.43 and a 1-year high of $20.92. The stock has a market cap of $57.38 billion, a price-to-earnings ratio of 130.01 and a beta of 1.00. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.79 and a current ratio of 1.13.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Wednesday, May 13th. The company reported $0.13 earnings per share for the quarter. Takeda Pharmaceutical had a net margin of 1.37% and a return on equity of 13.80%. The firm had revenue of $7.09 billion during the quarter. As a group, sell-side analysts forecast that Takeda Pharmaceutical Co Ltd will post 2.04 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Featured Article: Compound Interest

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co Ltd (NYSE:TAK).

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.